Hypothesis

Macrophage-secreted exosomes enriched in miR-21 directly reprogram vascular smooth muscle cells (VSMCs) toward an osteogenic phenotype, thereby mediating arterial calcification and stiffness independently of classic inflammatory cytokines.

Mechanistic Rationale

The context establishes that immune cells actively drive vascular calcification via IL-1β, TNF-α, and TGF-β signaling, yet even "anti-inflammatory" macrophages promote calcification through TGF-β secretion [4]. This paradox suggests that immune-mediated pathology extends beyond soluble cytokines to include vesicular communication. Recent work shows that senescent cells and macrophages release exosomes carrying specific microRNAs that alter recipient cell transcriptome [2]. miR-21 is a well-documented regulator of VSMC phenotype, suppressing PTEN and activating AKT/mTOR pathways that promote osteogenic differentiation [3]. We hypothesize that macrophage-derived exosomes deliver miR-21 to VSMCs, suppressing contractile markers (e.g., α‑SMA, SM22α) and upregulating osteogenic runners (RUNX2, Osterix) through PTEN/AKT signaling, thereby creating a feed‑forward loop where calcified VSMCs further secrete SASP factors that recruit more macrophages.

Testable Predictions

1. Exosomes isolated from aged murine macrophages will contain higher miR-21 levels than those from young macrophages, and this increase will correlate with VSMC calcification in vitro.
2. Pharmacological inhibition of exosome release (e.g., using GW4869) or genetic knockout of miR-21 in macrophages will reduce VSMC osteogenic signaling and arterial stiffness in aged mice, without altering systemic cytokine levels.
3. Transfer of miR-21‑enriched exosomes from aged macrophages to young VSMCs will recapitulate osteogenic transformation, whereas exosomes from miR-21‑deficient macrophages will not.
4. VSMCs treated with macrophage exosomes will show decreased PTEN phosphorylation and increased AKT activity, effects rescued by PTEN overexpression or miR‑21 antagomiRs.

Experimental Approach

• Exosome isolation: Harvest bone‑marrow derived macrophages from young (3 mo) and aged (24 mo) mice; ultracentrifuge to obtain exosomes; quantify miR‑21 by qPCR.
• In vitro calcification: Treat primary mouse VSMCs with exosomes (± GW4869 or miR‑21 inhibitor); assess Alizarin Red staining, RUNX2/Osterix expression, and PTEN/AKT signaling.
• In vivo validation: Administer GW4869 or macrophage‑specific miR‑21 knockout via lentiviral Cre to aged ApoE‑/‑ mice; monitor pulse wave velocity, arterial calcification (von Kossa), and cytokine panels over 8 weeks.
• Rescue experiments: Inject miR‑21‑enriched exosomes into young mice to determine if they accelerate stiffness; co‑inject PTEN‑overexpressing VSMC‑targeted liposomes to test specificity.

If exosomal miR‑21 is a primary driver, targeting this vesicle‑mediated axis should attenuate arterial aging even when global inflammation remains unchanged, shifting the therapeutic focus from broad immunosuppression to precision modulation of immune‑cell‑derived extracellular vesicles.